A Synergistic and Efficient Thrombolytic Nanoplatform: A Mechanical Method of Blasting Combined with Thrombolytic Drugs
Liu Hu,Jie Xu,Wenli Zhang,Junrui Wang,Ni Fang,Ying Luo,Lian Xu,Jia Liu,Yu Zhang,Haitao Ran,Dajing Guo,Jun Zhou
DOI: https://doi.org/10.2147/IJN.S382964
IF: 7.033
2022-11-10
International Journal of Nanomedicine
Abstract:Liu Hu 1, 2 &ast, Jie Xu 1 &ast, Wenli Zhang, 1, 2 Junrui Wang, 1, 2 Ni Fang, 1, 2 Ying Luo, 1, 2 Lian Xu, 1, 2 Jia Liu, 1 Yu Zhang, 1 Haitao Ran, 3 Dajing Guo, 1 Jun Zhou 1 1 Department of Radiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China; 2 Chongqing Key Laboratory of Ultrasound Molecular Imaging & Department of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China; 3 Department of Ultrasound, Institute of Ultrasound Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jun Zhou, Tel +86 23 6288 7295, Email Background and Objective: Thrombosis is a common disease that poses a great threat to life and health. Most thrombolytic effects of traditional treatments or nanomedicine are not efficient or safe enough. Therefore, we designed a nanoparticle (NP) with a combination of a phase transition material and thrombolytic drugs for efficient and safe thrombolysis. Methods: A thrombus fibrin-targeted and phase transition NP was designed and contained perfluorohexane (PFH) and the thrombolytic drug rtPA core, with CREKA polypeptides attached to the shell of the PLGA NPs. Characterization of the phase transition and ultrasound imaging of the NPs was carried out under low-intensity focused ultrasound (LIFU). LIFU-responsive drug release in vitro was also explored. Under the synergistic effect of PFH and rtPA, the efficient thrombolysis ability of the NPs was studied in vitro and in vivo. In vivo monitoring of thrombosis and biosafety were also verified. Results: The PPrC NPs had good ultrasound imaging ability under LIFU irradiation and were related to the phase transition characteristics of the NPs. CREKA polypeptides can effectively increase the aggregation of the NPs on thrombi. Under static and dynamic conditions in vitro, the "liquid to gas" transformation effect of PFH can perform the destruction function of the excavator at the thrombus site and promote the specific release of rtPA, and the subsequent rtPA drug thrombolysis can further fully dissolve the thrombus. In vivo experiments showed that the NPs can monitor the formation of thrombi and have good thrombolytic effects, with significantly reduced bleeding side effects. The biochemical indexes of the rats were within normal limits after treatment. Conclusion: PPrC NPs loaded with PFH and rtPA combining a mechanical way of blasting with thrombolytic drugs may be a promising new and reliable approach for thrombus monitoring and treatment. Keywords: low-intensity focused ultrasound, thrombolysis, PFH, rtPA, phase transition Thrombosis is the pathological basis of three major cardiovascular diseases, namely, myocardial infarction, cerebral apoplexy and venous thromboembolism, 1 which are serious threats to human health. 2,3 At present, there are two main methods of clinical treatment for thrombosis: drug thrombolysis and interventional surgery. The most commonly used thrombolytic drug is recombinant tissue plasminogen activator (rtPA). However, rtPA has a low bioavailability and poor targeting ability and easily causes side effects such as bleeding. Interventional surgery is an invasive treatment method with high technical requirements, complex surgical conditions, and high price, making it difficult to use in large populations. 4 Therefore, there is an urgent need to find a safer and more effective thrombolytic therapy. Due to the disadvantages of traditional thrombolysis, researchers have turned their focus to nanomedicine. By targeting nanodrugs into thrombi, drugs can be accurately released in a controllable time and space to treat thrombi and reduce complications. It has been reported that under the action of an external magnetic field, magnetic NPs can be passively delivered to the thrombus site, and then the drug is released accurately. 5–8 However, passively targeting thrombi is inconvenient, and the desired clinical outcome is difficult to achieve. Huang et al reported a liposome platform loaded with cRGD polypeptide, and this platform utilized the advantage of cRGD to actively target activated platelets; as a result, this platform achieved good thrombolytic effects in vitro. 9 To improve the biocompatibility of NPs, Chen et al modified the surface of NPs with a cell membrane, which prolonged their blood circulation time and effectively enha -Abstract Truncated-